We therefore investigated the use of the aromatase inhibitor anastrozole in combination with everolimus in patients with ER and/or PR-positive breast and gynecologic tumors including ovarian and endometrial cancer (trial registration ID: NCT01197170) and including an analysis of molecular data. This evidence concerns the gene ESR1 and endometrial cancer.